Market Trends of China Drug Delivery Devices Industry
The Autoinjectors Segment is Expected to Hold Significant Market Share Over the Forecast Period
The autoinjectors segment is expected to grow significantly due to increasing technological advancements, collaborations, and partnerships among companies for autoinjectors and the increased burden of chronic diseases. For instance, in January 2023, Yuanda Pharmaceuticals stated that its innovative products achieved phased results of the Jext prefilled epinephrine autoinjector pen for treating severe allergic reactions and received approval in the Greater Bay, China. These new product approvals may increase the availability and usage of autoinjectors in China, which is expected to boost the segment growth over the forecast period.
Furthermore, the high burden of cardiovascular diseases, such as coronary heart disease and stroke, is expected to increase drug treatments that can be delivered using autoinjector devices. For instance, the China Cardiovascular Health and Disease Report 2022, published in June 2023, reported 330 million cardiovascular diseases, which include 13 million strokes, 11.39 million coronary heart disease, 8.9 million heart failure, and 245 million hypertension cases in 2022. This shows the high burden of cardiovascular diseases, which is expected to boost the usage of autoinjector devices for drug delivery in treatment, increasing the segment growth over the study period.
Thus, due to the factors mentioned above, such as the high burden of chronic diseases and product approvals, the autoinjectors segment is expected to grow significantly during the forecast period.
The Pulmonary Disease Segment is Expected to Hold the Significant Market Share During the Forecast Period
Pulmonary disease is a type of disease that affects the lungs and other parts of the respiratory system. Pulmonary diseases can be caused by infection, smoking tobacco, or breathing in second-hand tobacco smoke, radon, asbestos, or other forms of air pollution. Some of the most common pulmonary diseases are chronic obstructive pulmonary disease (COPD), occupational lung diseases, asthma, and pulmonary hypertension. Pulmonary drug devices help inhale through the mouth and deposit it in the lower airways. The pulmonary diseases segment is expected to hold a significant market share owing to the rise in prevalence of this disease in the country and the demand for drug-delivery devices.
According to the study published in Value in Health Regional Issues in November 2022, between 2020 and 2039, China was expected to experience a rise in the number of COPD patients from 88.3 million to 103.3 million, accompanied by a 31% rise in severe cases. Thus, the significant burden of COPD in the country is expected to propel the segment's growth over the forecast period.
The market player strategies, such as product approvals and launches, are expected to boost the segment growth. For instance, in November 2023, Nanchang Baiji Medicine Technology Co. Ltd obtained the approval of the National Medical Products Administration (NMPA) for the budesonide nasal spray. Hence, these approvals increase the availability of drug-delivery devices for respiratory diseases, which is expected to drive the segment growth over the forecast period.
